GlassScriptPhysician profile
Jaime A Quesada
NPI 1578563862
$7,896.73
in general payments reported to CMS, 2019-2025
32 companies · $1,315 in 2025
The $1,315 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,147 · 2020: $629 · 2021: $815 · 2022: $892 · 2023: $1,574 · 2024: $1,524 · 2025: $1,315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,354 · Education: $58.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,353.68 |
| Education | $58.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,847.46 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $1,502.53 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Mylan Specialty L.P. | $595.08 | 2019-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $490.79 | 2019-2025 | Ofev, Jascayd |
| Genzyme Corporation | $456.97 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $414.73 | 2021-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $222.14 | 2019-2024 | Uptravi, Opsumit |
| Insmed, INC. | $156.86 | 2019-2025 | Arikayce |
| Grifols USA, LLC | $155.78 | 2019-2022 | |
| Amgen INC. | $91.86 | 2023-2025 | Tezspire |
| Inogen, INC. | $86.91 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Novartis Pharmaceuticals Corporation | $83.70 | 2019-2022 | |
| United Therapeutics Corporation | $82.10 | 2019-2020 | |
| Viatris Specialty LLC | $76.99 | 2025 | Yupelri |
| Philips North America LLC | $64.12 | 2019-2024 | (Ak6) Vest Therapy |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $58.98 | 2019-2020 | |
| Genentech USA, INC. | $56.51 | 2019-2020 | |
| Verona Pharma, INC. | $54.04 | 2025 | Ohtuvayre |
| Abbvie INC. | $52.61 | 2022 | |
| Gilead Sciences, INC. | $44.36 | 2022-2023 | Veklury |
| Electromed, INC. | $42.91 | 2019-2023 | Smartvest |
| Teva Pharmaceuticals USA, INC. | $38.03 | 2021 | |
| Biogen, INC. | $37.10 | 2021 | |
| Mallinckrodt Hospital Products INC. | $30.71 | 2025 | Acthar |
| Advanced Respiratory, INC | $22.88 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $21.54 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.15 | 2024 | |
| Tactile Systems Technology INC | $19.59 | 2025 | Nimbl, Flexitouch Plus |
| Takeda Pharmaceuticals U.S.A., INC. | $19.56 | 2024 | Glassia |
| Eurofins Viracor, LLC | $17.09 | 2024 | |
| Pfizer INC. | $16.63 | 2023 | |
| Baxter Healthcare | $16.02 | 2024 | Hillrom - Vest System Model 105 Home Care |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Quesada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.